Table 1

Baseline characteristics

N=3448TCZ-IV n=2414nTCZ-SC n=1034nP values
Total no of visits (median (IQR))4 (2–8)2 (1–4)
Total patient-years6094.31298.4
Age, years (median (IQR))56.6 (47.7–64.5)241457.3 (48.6–65.3)10340.17
Female gender, n (%)1923 (79.7)2414850 (82.2)10340.09
Ever smoker456 (32.1)1420202 (29.0)6960.16
BMI (median (IQR))25.6 (22.6–29.1)195026.2 (23.1–29.6)7190.02
Disease duration, years (median (IQR))6.2 (2.7–12.3)19506.7 (2.8–13.0)7470.39
Seropositivity (RF and/or ACPA), n (%)1572 (80.0)2139663 (81.4)8140.41
Previous bDMARDs, n (%)22669640.47
 None692 (30.5)319 (33.1)
 1921 (40.6)387 (40.1)
 2474 (20.9)185 (19.2)
 ≥3179 (7.9)73 (7.6)
Glucocorticoids1436 (61.6)2332605 (60.9)9930.75
Glucocorticoid dose, mg/day (median, IQR)5.0 (5.0–10.0)10755.0 (5.0–10.0)3610.67
Concomitant csDMARD23721020<0.001
 None675 (28.5)284 (27.8)
 MTX960 (40.5)317 (31.1)
 MTX+other csDMARDs295 (12.4)175 (17.2)
 Other than MTX442 (18.6)244 (23.9)
DAS28 (median (IQR))4.4 (3.4–5.9)24144.1 (3.3–5.5)1034<0.001
CDAI (median (IQR))17.0 (13.5–28.4)241417.0 (15.0–24.7)10340.1
HAQ (median (IQR))1.1 (0.9–1.7)24141.0 (1.0–1.5)10340.02
TJC (over 28 joints) (median (IQR))8.0 (3.0–14.0)19336.0 (2.0–11.0)887<0.001
SJC (over 28 joints) (median (IQR))6.0 (2.0–10.0)19364.0 (2.0–8.0)890<0.001
PGA (median (IQR))57.0 (10.0–80.0)165360.0 (25.0–78.0)6460.24
PhGA (median (IQR))40.0 (6.0–68.0)154040.0 (13.5–60.0)6390.98
ESR (mm/hour) (median (IQR))27.0 (10.0–46.0)177022.0 (10.0–41.0)6580.02
CRP (mg/L) (median (IQR))9.0 (3.0–25.8)19216.7 (2.0–19.3)863<0.001
Education category11013610.03
 0–10 years394 (35.8)127 (35.2)
 11–13 years538 (48.9)158 (43.8)
 >13 years169 (15.3)76 (21.1)
Comorbidities1310 (61.5)2129524 (58.4)8970.12
No of patients for each route of delivery since 2014 by year of treatment initiation
2014348 (80.9 %)82 (19.1%)
2015260 (41.9%)361 (58.1%)
2016183 (35.3%)336 (64.7%)
2017–201891 (28.7%)226 (71.3%)
  • ACPA, anti–citrullinated protein antibody; BMI, body mass index; CDAI, Clinical Disease Activity Index; DAS28, Disease Activity Score 28; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IQR, interquartile range; MTX, methotrexate; PGA, patient global assessment; PhGA, Physician global assessment; RF, rheumatoid factor; SJC, swollen joint counts; TCZ-IV, intravenous tocilizumab; TCZ-SC, subcutaneous tocilizumab; TJC, tender joint counts; bDMARDs, biological disease-modifyingantirheumatic drugs; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs.